Correction: *Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer*

Chen P, Zhang L, Zhang W, *et al.* Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer. *J Immunother Cancer* 2020;8:e001391. doi:10.1136/jitc-2020-001391.

This article has been corrected since it was first published. Additional footnotes have been added to Table 1 for clarification, and the following sentence has been added to the Results section: ‘The median RFS calculated by the KM analysis was 32.0 months. In addition, the median RFS calculated by the KM analysis of stage I–II and stage III SCLC was 63.0 months, and 14.7 months, respectively.’.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See <https://creativecommons.org/licenses/by/4.0/>.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

J Immunother Cancer 2021;9:e001391corr1. doi:10.1136/jitc-2020-001391corr1